text: <unk>  is a calcium-sensing receptor agonist that is FDA approved for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.   Common adverse reactions include blood calcium decreased, muscle spasms, diarrhea, nausea, vomiting, headache, hypocalcemia, and paresthesia.
option_0: Etelcalcetide
option_1: Drotrecogin alfa
option_2: Trenonacog alfa
option_3: Pasireotide
option_4: Fludroxycortide
option_5: Prothipendyl
option_6: Neostigmine methylsulfate
option_7: Procyclidine hydrochloride